OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Eastern Cooperative Oncology Group Performance Status Worsened reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,227 reports · 53 co-occurring drugs

As of the last recalculation, Eastern Cooperative Oncology Group Performance Status Worsened appears in 1,227 FAERS reports alongside 53 co-occurring drug terms. The strongest observed disproportionality signal is NIRAPARIB (PRR 108.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Niraparib127108.2108.8
Durvalumab7263.763.9
Ribociclib9052.152.3
Pembrolizumab23346.146.2
Ado-Trastuzumab Emtansine2143.043.1
Temozolomide4941.041.1
Dexamethasone Sodium Phosphate2033.934.0
Fam-Trastuzumab Deruxtecan-Nxki1830.730.8
Pemetrexed3730.230.2
Fulvestrant5529.529.6
Exemestane3528.528.5
Letrozole Tablets6825.325.4
Pemetrexed Disodium5425.125.1
Polatuzumab Vedotin1322.822.9
Letrozole7020.420.4
Carboplatin13119.519.5
Bendamustine Hcl1718.818.9
Pertuzumab2616.616.6
Zoledronic Acid3816.516.6
Paclitaxel8615.815.8
Paclitaxel (Aibumin-Bound)7115.515.5
Regorafenib1014.714.7
Irinotecan Hydrochloride1114.614.6
Dalteparin Sodium914.514.5
Doxorubicin Hydrochloride2613.813.8
Anastrozole Tablets1713.613.6
Bevacizumab9213.513.6
Fondaparinux Sodium612.612.6
Sorafenib1512.412.4
Fluorouracil4810.910.9
Fluorouracil Cream, 0.5%4710.810.8
Cisplatin4810.810.8
Atezolizumab2410.710.7
Gemcitabine Hydrochloride3210.510.5
Trastuzumab4110.410.5
Olaparib129.89.8
Lenvatinib189.49.4
Crizotinib79.49.4
Aprepitant109.39.3
Palbociclib458.38.3
Vincristine Sulfate148.28.2
Panitumumab77.67.6
Doxorubicin367.07.0
Brentuximab Vedotin46.66.6
Gemcitabine156.56.5
Cabozantinib186.46.4
Axitinib76.16.1
Bendamustine Hydrochloride45.75.7
Abiraterone45.05.0
Enzalutamide154.44.4
Osimertinib84.34.3
Velpatasvir And Sofosbuvir34.04.0
Lutetium Lu 177 Vipivotide Tetraxetan33.93.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.